Mealey's (April 8, 2018, 10:35 PM EDT) -- ALEXANDRIA, Va. — Allegations that a claimed method for improving the viral safety of liquid compositions comprising “Factor VII” (FVII) — a protein involved in the blood clotting process — is obvious were not proven by a preponderance of the evidence, the Patent Trial and Appeal Board ruled April 5 (Laboratoire Francais du Fractionnement et des Biotechnologies S.A. v. Novo Nordisk Healthcare AG, No. IPR2017-00028, PTAB)....